Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-08-02
2005-08-02
Foley, Shanon A. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
06923970
ABSTRACT:
Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.
REFERENCES:
patent: 5417986 (1995-05-01), Reid
patent: 5439809 (1995-08-01), Haynes
patent: 5571712 (1996-11-01), Haynes
patent: 5583112 (1996-12-01), Kensil
patent: 6080408 (2000-06-01), Rovinski et al.
patent: 6121021 (2000-09-01), Rovinski et al.
patent: 6451322 (2002-09-01), Rovinski et al.
patent: 6544527 (2003-04-01), Rovinski et al.
patent: WO 89/05349 (1989-06-01), None
patent: WO 91/05860 (1990-05-01), None
patent: WO 91/05864 (1991-05-01), None
patent: WO 91/07425 (1991-05-01), None
patent: WO 93/20220 (1993-10-01), None
patent: WO 96/05292 (1996-02-01), None
Klein, M et al., Development of a cross-neutralizing HIV-1 pseudovirion-based vaccine. AIDS research and human retroviruses. vol. 9, (1993) p. S33 XP000560222.
Aldovini, A. et al., Mutations of RNA and protein sequences involved in Human Immunodeficiency virus type packaging result in production of noninfectious virus., vol. 64, No. 5 (1993) pp. 1920-1926.
Kieny, M.P., Structure and regulation of the human AIDS virus. (1990) J. Acquired Immune Deficiency Syndromes, 3, pp. 395-402.
Ulmer, J.B., et al., Polynucleotides vaccines. (1993) Curr. Opin. Invest. Drugs vol. 2, No. 9 pp. 983-989.
Trifilieff, E., et al., Antigen cross-reactivity potential of synthetic peptides immobilized on polyethylene rods. (1991) Mol. Immunol., 28, 889-896.
Rovinski, B., et. al., Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins . . . AIDS vaccines. (1992) J. Virol, 66, pp. 4003-4012.
Wain-Hobson, S., et al., Nucleotide sequence of the AIDS virus, LAV (1985) Cell, 40, pp. 9-17.
Myers, G. et al., (1990) Human retroviruses and AIDS. Theoriteical Biology and Biophysics Group T-10, Los Alamos National Library, N. Mex.
Alizon, M., et al., Molecualr cloning of lymphadenopathy-associated virus. (1984) Nature, 312, pp. 757-780.
Min Jou, W., et al., Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined form cloned DNA. (1980) Cell, 19, pp. 683-696.
Westhof, E., et al., Correlation between segmental mobility and the location of antigenic determinants in porteins. (1984) Nature, 312, 123-126.
Sakalian, M. et al., Effieciency and selectivity of RNA packaging by Rous Sarcoma Virus gag deletion mutatis. J. of Virology. vol. 68, No. 9, (1994) pp. 5969-5981. XP000560252.
Zhang, Y. & Barklis, E. Necleocapsid protein effects on the specificity of retrovirus RNA encapsidation. J. of Virology. vol. 69, No. 9 pp. 5716-5722. XP002003498.
Haynes, R.J. et al., Production of Immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. vol. 7, No. 1, (1991) pp. 17-27.
Bowles, et al., Site-directed mutagenesis of the P2 region of the Rous Sarcoma Virus gag gene: effects on gag polyprotein processing. J. of Virology., vol. 68, No. 9 (1994) pp. 20-28. XP002003497.
Dannull, J. et al., Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-teminal zinc finger and flanking basic amino acid residues. (1994) vol. 13, No. 7 pp. 1525-1533.
Dupraz P., et al., Point mutations in the proximal Cys-His Box of Rous Sarcoma virus nucleocapsid protein. J. of Virology (1990) Vo. 64, No. 10, pp. 4978-4987.
Wakefield, K. J. et al., In vitro enzymatic activity of Human Immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD Amino Acid Motif correlates with the infectious potencial of the proviral genome. (1992) vol. 66, No. 11, pp. 6806-6812.
Gorelick, J. R. et al., noninfectious human immunodeficiency virus type 1 mutants deficient in Genomic RNA. (1990) vol. 64, No. 7, pp. 3207-3211.
Martin, L.J. et al.,, Biochemical analysis of human immunodeficiency virus-1 reverse transcriptase containing a mutation at position lysine 263. vol. 268, No. 4, pp. 2565-2570.
Edelman, R. and Tacket, C., Adjuvants. (1990), pp. 51-66.
Berman W.P. et al., Protection of chimpazees from infection by HIV-1 after vaccination with recombinant glycoprotein gp 120 but not gp 160. (1990) vol. 345, pp. 622-625.
Cao Shi-Xian
Klein Michel H.
Persson Roy
Rovinski Benjamin
Yao Fei-Long
Foley Shanon A.
Sanofi Pasteur Limited
Sim & McBurney
LandOfFree
Retrovirus-like particles made non-infectious by a plurality... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retrovirus-like particles made non-infectious by a plurality..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retrovirus-like particles made non-infectious by a plurality... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446316